Literature DB >> 24671448

Surgeon-modified fenestrated endograft to treat ruptured juxtarenal aneurysm.

George T Pisimisis1, Panagiotis Kougias1, Neal R Barshes1, Carlos F Bechara1.   

Abstract

IMPORTANCE: No endovascular devices are commercially available in the United States to treat high-surgical risk patients with aneurysms extending to visceral arteries. Treatment options are even further limited for symptomatic patients in need of urgent treatment.
OBJECTIVE: To describe a successful urgent endovascular repair of a juxtarenal abdominal aortic aneurysm with contained rupture. DESIGN, SETTING, AND PARTICIPANTS: A hybrid suite using a surgeon-modified fenestrated endovascular graft and advanced 3-dimensional imaging workstation. The patient was an 82-year-old veteran taking clopidogrel and aspirin for coronary stents with significant cardiopulmonary comorbidities including multiple prior abdominal surgeries and a single functional left kidney. INTERVENTION: Surgeon-modified fenestrated endovascular aortic aneurysm repair. MAIN OUTCOMES AND MEASURES: Clinical, laboratory, and radiographic improvement.
RESULTS: The patient was discharged 5 days after an uneventful postoperative course. On short-term follow-up, the patient had an early return to his baseline functional status. The excluded aneurysm sac shrank with patent visceral branches and there was an absence of endoleak on 3-month and 6-month surveillance computed tomography angiography. CONCLUSIONS AND RELEVANCE: Surgeon-modified fenestrated stent grafts may be a viable option for selected high-surgical risk patients with symptomatic complex abdominal aortic aneurysms.

Entities:  

Mesh:

Year:  2014        PMID: 24671448     DOI: 10.1001/jamasurg.2013.4154

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  1 in total

1.  Intraoperative adverse events and early outcomes of custom-made fenestrated stent grafts and physician-modified stent grafts for complex aortic aneurysms.

Authors:  Jean Nicolas Sénémaud; Iannis Ben Abdallah; Paul de Boissieu; Joseph Touma; Hicham Kobeiter; Pascal Desgranges; Jean-Pierre Becquemin; Frédéric Cochennec
Journal:  J Vasc Surg       Date:  2019-11-07       Impact factor: 4.268

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.